NCT06947967View on ClinicalTrials.gov

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

PHASE3RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

August 12, 2025

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2032

Conditions
Lymphoma, T-Cell, Peripheral
Interventions
DRUG

CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)

Cyclophosphamide 750 mg/m2 , intravenous infusion on day 1 of each 21-day cycle. Doxorubicin 70mg/m2 , intravenous infusion on day 1 of each 21-day cycle, total 6 cycles. Vincristine 1.4mg/m2(Max dose 2mg), intravenous injection on day 1 of each 21-day cycle , total 6 cycles. Prednisone 100 mg, oral, day 1-5 of each 21-day cycle,total 6 cycles.

DRUG

Tucidinostat

oral, taking as prescribed by the protocol

DRUG

Placebo

oral, taking as prescribed by the protocol

Trial Locations (1)

510050

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY

NCT06947967 - Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype | Biotech Hunter | Biotech Hunter